Abstract
The successful treatment of lung cancer, as with all cancers, is determined by the selectivity of the therapy. That is, the cells that have undergone carcinogenic changes must be eradicated, while normal cells must be preserved. With therapeutic agents that are not discriminating, significant side effects and toxicity may result. In fact, death is not rare. Because progress towards the successful treatment of lung cancer has been minimal, it is noteworthy that the lung does offer an inherent advantage (1, 2). This advantage arises from its accessibility without invasive procedures. Moreover, this accessibility can increase selectivity, because therapy can be not only directed exclusively to the lung but also limited to the lung as well.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wattenberg, L., Wiedmann, T. S., Estensen, R. D., Zimmerman, C. L., Steele, V. E., and Kelloff, G. J. (1998) Chemoprevention of pulmonary carcinogenesis by aerosolized budensonide in female A/J mice. Cancer Res. 57, 5489–5492.
Wattenberg, L., Wiedmann, T. S., Estensen, R. D., Zimmerman, C. L., Steele, V. E., and Kelloff, G. J. (2000) Chemoprevention of pulmonary carcinogenesis in female A/J mice by brief exposures to aerosolized budensonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myoinositol. Carcinogenesis 21, 179–182.
Estensen, R. D. and Wattenberg, L. W. (1993) Studies of chemopreventive effects of myo-inositol on benzo(a)pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14, 1975–1977.
Wiedmann, T. S., Bhatia, R., and Wattenberg, L. W. (2000) Drug solubilization in lung surfactant. J. Control. Rel. 65, 43–47.
Wattenberg, L. W. (1993) Prevention-therapy-basic science and the resolution of the cancer problem presidential address. Cancer Res. 53, 5890–5896.
Grant, D. J. W. and Higuchi, T. (1990) Solubility behavior of organic compounds, in Techniques of Chemistry, vol. 21 (Saunders, Jr., W. H., ed.), John Wiley and Sons, NY, pp. 12–88.
King, R. J. and Clements, J. A. (1972) Surface active materials from dog lung. II. Composition and physiological correlations. Am. J. Physiol. 223, 715–726.
Possmayer, F. (1990) The role of surfactant-associated proteins. Am. Rev. Respir. Dis. 142, 749–752.
Stratton, C. J. (1977) The periodicity and architecture of lipid retained and extracted lung surfactant and its origin form multilamellar bodies. Tissue Cell 9, 301–316.
Chen, Jr., P. S., Toribara, T. Y., and Warner, H. (1956) Microdetermination of phosphorus. Anal. Chem. 28, 1756–1758.
Cai, X., Grant, D. J. W., and Wiedmann, T. S. (1997) Solubilization of drugs by bile salts and bile salt/phospholipid aggregates. J. Pharm. Sci. 86, 372–377.
Whitsett, J. A., Ohning, B. L., Ross, G., Meuth, J., Weaver, T., Holm, B. A., et al. (1986) Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr. Res. 20, 460–467.
Possmayer, F., Yu, Su., and Weber, M. (1984) Calcium-protein-lipid interactions in pulmonary surfactant. Prog. Resp. Res. 18, 112–120.
Oosterlaken-Dijksterhuis, J. A., Haagsman, H. P., van Golde, L. M. G., and Demel, R. A. (1991) Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 30, 8276–8281.
Claypool, W. D., Wang, D. L. Chander, A., and Fisher, A. B. (1984) An ethanol/ether soluble apoprotein from rat lung surfactant augments liposome uptake by isolated granular pneumocytes. J. Clin. Invest. 74, 677–684.
Keough, K. M. W., Farrell, E., Cox, M., Harrell, G., and Taeusch, Jr., H. W. (1985) Physical, chemical, and physiological characteristics of isolates of pulmonary surfactant from adult rabbits. Can. J. Physiol. Pharmacol. 63, 1043–1051.
King, R. J. and Clements, J. A. (1972) Surface active materials from dog lung. I. Method of isolation. Am. J. Physiol. 223, 707–714.
Ryan, S. F., Hashim, S. A., Cernansky, G., Barrett, Jr., C. R., Bell, Jr., A. L. L., and Liau, D. F. (1980) Quantification of surfactant phospholipids in the dog lung. J. Lipid Res. 21, 1004–1014.
Shiffer, K., Hawgood, S., Duzgunes, N., and Goerke, J. (1988) Interactions of the low molecular weight group surfactant-associated proteins (SP 5-18) with pulmonary surfactant lipids. Biochemistry 27, 2689–2695.
Yu, S.-H. and Possmayer, F. (1988) Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant. Biochim. Biophys. Acta 961, 337–350.
Shelley, S. A., Balis, J. U., Paciga, J. E., Espinoza, C. G., and Richman, A. V. (1982) Biochemical composition of adult human lung surfactant. Lung 160, 195–206.
Suwabe, A., Mason, R. J., Smith, D., Firestone, J. A., Browning, M. D., and Voelker, D. R. (1992) Pulmonary surfactant secretion is regulated by the physical state of extracellular phosphatidylcholine. J. Biol. Chem. 267, 19884–19890.
Li, C-Y., Zimmerman, C., and Wiedmann, T. S. (1996) Solubilization of retinoids by bile salt/phospholipid aggregates. Pharm. Res. 13, 907–913.
Hallman, M. (1989) Recycling of surfactant: a review of human amniotic fluid as a source of surfactant for treatment of respiratory distress syndrome. Rev. Perinat. Med. 6, 197–226.
Grant, D. J. W. and Higuchi, T. (1990) Solubility behavior of organic compounds, in Te chniques of Chemistry, vol. 21 (Saunders, Jr., W.H., ed.), John Wiley and Sons, NY, pp. 384–391.
Pham, S. and Wiedmann, T. S. (1999) A novel method for the rapid screening of poorly water soluble drugs for respiratory delivery. Pharm. Res. 16, 1857–1863.
Wiedmann, T. S. and Ravichandran, A. (2001) Ultrasonic nebulization system for respiratory drug delivery. Pharm. Dev. Technol. 6, 83–90.
CRC Handbook of Chemistry and Physics. (65th edition; West, R. C., ed.) CRC Press, New York, NY, 1984, pp. D192–D218.
Pham, S. and Wiedmann, T. S. (2001) Dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant. J. Pharm. Sci. 90, 98–104.
Higuchi, T., Shih, F.-M. L., Kimura, T., and Rytting, J. H. (1979) Solubility determination of barely aqueous-soluble organic solids. J. Pharm. Sci. 68, 1267–1272.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Wiedmann, T.S. (2003). Assessing the Interaction of Particulate Delivery Systems with Lung Surfactant. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:755
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:755
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols